A small Japanese study provides useful insights on determining the role of these agents in cancer care, but studies in larger, more diverse populations are needed
Newly-released ESMO recommendations critically assess specific germline pathogenic variants in terms of cancer-related mortality and testing implications for patients and their families
Novel evidence demonstrates the clinical utility of circulating tumour DNA in patients with HR+/HER2- cancers harbouring ESR1 and PIK3CA mutations
Findings from recently presented studies support an upfront integration of ADCs in the treatment course, but some key questions are pending
Two studies investigating efficacy of bispecific T-cell engager tarlatamab and lurbinectedin–atezolizumab combination met their primary endpoints of survival
Experts’ discussions during ESMO Breast 2025 provided an overview on promises and challenges in the field
Evidence is growing for a potential role of microplastics in cancer development, but more solid research is needed
Progress in artificial intelligence tools is opening-up novel modalities to provide education and doctor-patient communication
Reduced-dose chemoradiotherapy and non-surgical strategies show promising outcomes with fewer long-term side-effects in lower gastrointestinal cancers
Final data from the SGNTUC-019 trial support the use of the agent with trastuzumab in heavily pretreated patients
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.